DNLI Sep 2024 17.500 put
| Previous close | 3.6000 |
| Open | 3.6000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 17.50 |
| Expiry date | 2024-09-20 |
| Day's range | 3.6000 - 3.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireDenali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, which
Simply Wall St.Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.74 Denali...
ZacksWhy Denali Therapeutics (DNLI) Stock Might be a Great Pick
Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
